Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

16 ccRCC patients exomes and transcriptomes

ABSTRACT: Whole-exome and transcriptome sequencing data from 16 clear cell renal cell carcinoma patients

PROVIDER: PRJEB26348 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2538870_1.fastq.gz	Fastqsanger.gz
	ERR2538870_2.fastq.gz	Fastqsanger.gz
	ERR2538880_1.fastq.gz	Fastqsanger.gz
	ERR2538880_2.fastq.gz	Fastqsanger.gz
	ERR2538890_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 504

Similar Datasets

Expression data from spatially separated samples of different ccRCC patients

Project description:We have sampled several tumour regions from nine clear cell renal cell carcinoma (ccRCC) patients to investigate intra-tumour heterogeneity.

2014-01-06 | GSE53000 | GEO

Expression data from spatially separated samples of different ccRCC patients

Project description:We have sampled several tumour regions from nine clear cell renal cell carcinoma (ccRCC) patients to investigate intra-tumour heterogeneity. We selected 56 tumour samples and 6 normal samples from the 9 patients for expression analysis using microarray data. All samples were fresh frozen upon extraction.

2014-01-06 | E-GEOD-53000 | biostudies-arrayexpress

ccRCC WES

Project description:clear cell renal cell carcinoma (ccRCC) whole exome sequencing tumor-normal biopsy pair

| PRJEB14772 | ENA

Effect of everolimus on clear cell renal cell carcinoma (ccRCC) cell lines - parental and stem cells

Project description:The aim of this study was to compare effect of everolimus on growth of different renal cell carcinoma (RCC) populations and develop design for experiments to measure the early response of everolimus in clear cell RCC (ccRCC) cell lines including renal cancer stem cells. Gene expression profiling using microarray was performed to determine the early response to everolimus after 3 days of treatment with optimizied concentration of drug in two ccRCC cell lines 1) parental clear cell renal cell carcinoma ccRCC-PCSC (HKPCSC -human parental kidney cancer stem cells) and 2) ccRCC-CSC - clear cell renal cell carcinoma -cancer stem cells (HKCSC - human kidney cancer stem cells).

2018-05-31 | GSE106819 | GEO

89 ccRCC UMI panel

Project description:Gene panel sequencing data of 89 clear cell renal cell carcinoma patients (ccRCC)

| PRJEB26346 | ENA

miRNA transcript levels in ccRCC-derived cell lines and proximal tubular epithelial cell samples

Project description:Despite numerous studies reporting deregulated microRNA (miRNA) and gene expression patterns in clear cell renal cell carcinoma (ccRCC), no direct comparisons have been made to its presumed normal counterpart; the renal proximal epithelial tubular cells (PTEC). The aim of this study was to determine the miRNA expression profiles of ten clear cell renal cell carcinoma-derived cell lines and short-term cultures of PTEC, and to correlate these with their gene expression, and copy-number profiles. Using microarray-based methods, a significantly altered expression level in ccRCC cell lines was observed for 23 miRNAs and 1630 genes. The set of miRNAs with significantly decreased expression levels include all members of the miR-200 family known to be involved in the epithelial to mesenchymal transition (EMT) process. Expression levels of 13 of the 47 validated target genes for the downregulated miRNAs were increased more than two-fold. Our data reinforce the importance of the EMT process in the development of ccRCC. For mRNA expression data of these cell lines see GEO Series accession number GSE20491. MicroRNA profiling was performed on two proximal tubular epithelial cell samples (both cell samples were hybridized twice (biological duplicates)) and ten clear cell renal cell carcinoma- derived cell lines (one of which; RCC-JF in duplicate)

2012-11-01 | E-GEOD-34981 | biostudies-arrayexpress

LC-MS/MS proteomic profiling study of ccRCC cell-lines

Project description:We conducted comparative proteomic analysis with clear cell renal cell carcinoma (ccRCC), a subtype of RCC, have poorer prognosis and metastasize to the lungs, bones and lymph nodes. Comparative proteomic analysis in ccRCC study will reveals novel insights and development of disease.

2025-05-06 | PXD045898 | Pride

A multiomics disease progression signature of low-risk ccRCC

Project description:Background: Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. Identification of ccRCC likely to progress, despite an apparent low risk at the time of surgery, represents a key clinical issue. Methods: From a cohort of adult ccRCC patients (n=443), we selected low-risk tumors progressing within a 5-years average follow-up (progressors: P, n=8) and non-progressing (NP) tumors (n=16). Transcriptome sequencing, miRNA sequencing and proteomics were performed on tissues obtained at surgery. Our work suggests that LXR, FXR and macrophage activation pathways could be critically involved in the inhibition of the progression of low-risk ccRCC. Furthermore, a 10-component classifier could support an early identification of apparently low-risk ccRCC patients.

2022-08-10 | GSE207557 | GEO

RNAseq of clear cell renal cell carcinoma (ccRCC) tumor specimens

Project description:RNAseq of clear cell renal cell carcinoma (ccRCC) tumor specimens

| PRJEB88258 | ENA

CNV data from 133 ccRCC samples

Project description:Approximately 70% of clear cell renal cell carcinoma are characterised by the biallelic inactivation of VHL on chromosome 3p. ELOC-mutated renal cell carcinoma with biallelic ELOC inactivation on chromosome 8q are considered a novel subtype of renal cancer possessing a morphological overlap with ccRCC; however, the frequency and consequences of ELOC alterations in wtVHL and mutVHL is unclear. In this study, we characterise 123 renal tumours with clear cell morphology with known VHL mutation status to assess morphological and molecular consequences of ELOC inactivation. Using Oncoscan and whole exome sequencing we identify 18 ELOC deleted RCC, three of which contain ELOC mutations resulting in the biallelic inactivation of ELOC. Biallelic ELOC and biallelic VHL aberrations were mutually exclusive, although two ELOC-mutated RCC showed monoallelic VHL alterations. Using High Ambiguity Driven Biomolecular Docking we report a novel ELOC variant containing a duplication event disrupting ELOC-pVHL interaction alongside the frequently seen Y79C alteration. Using HRM mass spectrometry we show RCC with biallelic ELOC alterations have significantly reduced ELOC expression but similar CAIX and VEGFA expression when compared to classical ccRCC with VHL inactivation. These data demonstrate that RCC with ELOC and VHL alterations have comparable downstream effects with similar pathways to ccRCC tumourigenesis indicating that both entities are closely related.

2025-04-22 | GSE201277 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data